Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan

Bone Marrow Transplant. 2023 Sep;58(9):1051-1053. doi: 10.1038/s41409-023-02019-y. Epub 2023 Jun 17.

Authors

Affiliations

¹ Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan. mizuki.haraguchi87@gmail.com.
² Department of Hematology, Toranomon Hospital, Tokyo, Japan.
³ Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan.
⁴ Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Hematologic Diseases* / complications
Hematologic Diseases* / therapy
Humans
Incidence
Japan / epidemiology
Pre-Exposure Prophylaxis*
Retrospective Studies

Substances

tixagevimab
cilgavimab